Up to 42 days
Check your eligibility now & get in touch with a study centerCHECK ELIGIBILITY
Learn more about participating in this clinical study.
Kidneys are the most common type of organ transplant. Even with the best matched kidney and pre/post care, rejections can occur. The body's immune system can recognize the kidney as a foreign thing, like a bacteria or virus, and can signal the body to attack. This is known as antibody-mediated rejection (AMR) after receiving a kidney transplant.
What is the purpose of the study?
This study will compare an investigational medication plus standard of care (SOC), treatment that is commonly used to treat AMR, to SOC alone to determine the safety and effectiveness of the investigational medication for the prevention and treatment of AMR.
Up to 42 days
Up to 49 weeks
Up to 52 weeks
To attend the scheduled visits and allow the tests or procedures to be performed as planned.
To inform the study doctor or study staff if any of the following circumstances occur:
What is a clinical research study?
Why are clinical trials conducted?
How do clinical trials work?
What is an investigational medication?
What is standard of care?
Why should I join a clinical research study?
Who can participate in a study?
What is an informed consent?
What is an open label study?
What is a Phase II (Phase 2) trial?
What type of study-related medical care is provided during a study?
Is it safe to participate in a clinical trial?
Can I speak with someone if I have questions?
I don't read/speak English well. Can I participate in the study?
Complete this brief questionnaire to help determine if you may qualify to participate in this clinical study and be referred to a site recruiting in your area for further evaluation.
You can also add your contact information to be notified of future Sanofi studies.
Health Resources & Services Administration: Organ Donation Statistics. Accessed at https://www.organdonor.gov/learn/organ-donation-statistics. Accessed May April 2022.
Sellares J, Freitas DG, Mengel M, Reeve J, Einecke G, Sis B, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant. 2012;12(2):388-99.
Gaston R, Cecka JM, Kasiske B, Fieberg AM, Leduc R, Cosio FC, et al. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation. 2010;90(1):68-74.
Loupy A and Lefaucheur C. Antibody-mediated rejection of solid-organ allografts. N Engl J Med. 2018;379(12):1150-60.
Version 1,0, 28Jun2022